Modified Carfilzomib Dosing is Associated with Improved Treatment Responses and Longer Time on Treatment in Patients with Multiple Myeloma
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Efentakis P, Kremastiotis G, Varela A, Nikolaou P, Papanagnou E, Davos C
. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2018; 133(7):710-723.
DOI: 10.1182/blood-2018-06-858415.
View
2.
Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A
. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3,.... Lancet Oncol. 2020; 21(10):1317-1330.
PMC: 7591827.
DOI: 10.1016/S1470-2045(20)30452-6.
View
3.
Tantawy M, Chekka L, Huang Y, Garrett T, Singh S, Shah C
. Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Front Cardiovasc Med. 2021; 8:645122.
PMC: 8116486.
DOI: 10.3389/fcvm.2021.645122.
View
4.
Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A
. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020; 21(12):e540.
DOI: 10.1016/S1470-2045(20)30635-5.
View
5.
Dimopoulos M, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R
. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2015; 17(1):27-38.
DOI: 10.1016/S1470-2045(15)00464-7.
View